Alternate-day treatment with crizotinib for drug-induced esophagitis and liver damage in a patient with EML4-ALK fusion gene-positive lung adenocarcinoma

Yoko Tsukita; Tatsuro Fukuhara; Maki Kobayashi; Mami Morita; Aya Suzuki; Kana Watanabe; Tetsuya Noguchi; Yasuko Kurata; Manabu Suno; Makoto Maemondo

doi:10.2169/internalmedicine.54.4996

Alternate-day treatment with crizotinib for drug-induced esophagitis and liver damage in a patient with EML4-ALK fusion gene-positive lung adenocarcinoma

Yoko Tsukita, Tatsuro Fukuhara, Maki Kobayashi, Mami Morita, Aya Suzuki, Kana Watanabe, Tetsuya Noguchi, Yasuko Kurata, Manabu Suno, Makoto Maemondo

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

A 44-year-old woman who was diagnosed with anaplastic lymphoma kinase-positive lung adenocarcinoma developed brain metastases, multiple spinal metastases and meningeal dissemination. Crizotinib was administered after the failure of first-line chemotherapy. Esophagitis and liver damage were induced by the twicedaily administration of crizotinib at 250 mg and 200 mg, respectively. The alternate-day administration of crizotinib (250 mg, twice daily) was able to control disease progression without any adverse effects for several months. We evaluated the relationship between the serum concentration of crizotinib and the development of esophagitis and liver damage. The alternate-day administration of crizotinib is one of the strategies for managing the severe toxicity of crizotinib.

Original language	English
Pages (from-to)	3185-3188
Number of pages	4
Journal	Internal Medicine
Volume	54
Issue number	24
DOIs	https://doi.org/10.2169/internalmedicine.54.4996
Publication status	Published - 2015 Dec 15
Externally published	Yes

Keywords

ALK rearrangement
Alternate-day administration
Crizotinib
Drug-induced esophagitis
Non-small-cell lung cancer

ASJC Scopus subject areas

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.54.4996

Cite this

Tsukita, Y., Fukuhara, T., Kobayashi, M., Morita, M., Suzuki, A., Watanabe, K., Noguchi, T., Kurata, Y., Suno, M., & Maemondo, M. (2015). Alternate-day treatment with crizotinib for drug-induced esophagitis and liver damage in a patient with EML4-ALK fusion gene-positive lung adenocarcinoma. Internal Medicine, 54(24), 3185-3188. https://doi.org/10.2169/internalmedicine.54.4996

Tsukita, Y, Fukuhara, T, Kobayashi, M, Morita, M, Suzuki, A, Watanabe, K, Noguchi, T, Kurata, Y, Suno, M & Maemondo, M 2015, 'Alternate-day treatment with crizotinib for drug-induced esophagitis and liver damage in a patient with EML4-ALK fusion gene-positive lung adenocarcinoma', Internal Medicine, vol. 54, no. 24, pp. 3185-3188. https://doi.org/10.2169/internalmedicine.54.4996

@article{820f0b9eb68b4059abfcc9d586271a14,

title = "Alternate-day treatment with crizotinib for drug-induced esophagitis and liver damage in a patient with EML4-ALK fusion gene-positive lung adenocarcinoma",

abstract = "A 44-year-old woman who was diagnosed with anaplastic lymphoma kinase-positive lung adenocarcinoma developed brain metastases, multiple spinal metastases and meningeal dissemination. Crizotinib was administered after the failure of first-line chemotherapy. Esophagitis and liver damage were induced by the twicedaily administration of crizotinib at 250 mg and 200 mg, respectively. The alternate-day administration of crizotinib (250 mg, twice daily) was able to control disease progression without any adverse effects for several months. We evaluated the relationship between the serum concentration of crizotinib and the development of esophagitis and liver damage. The alternate-day administration of crizotinib is one of the strategies for managing the severe toxicity of crizotinib.",

keywords = "ALK rearrangement, Alternate-day administration, Crizotinib, Drug-induced esophagitis, Non-small-cell lung cancer",

author = "Yoko Tsukita and Tatsuro Fukuhara and Maki Kobayashi and Mami Morita and Aya Suzuki and Kana Watanabe and Tetsuya Noguchi and Yasuko Kurata and Manabu Suno and Makoto Maemondo",

note = "Publisher Copyright: {\textcopyright} 2015 The Japanese Society of Internal Medicine.",

year = "2015",

month = dec,

day = "15",

doi = "10.2169/internalmedicine.54.4996",

language = "English",

volume = "54",

pages = "3185--3188",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "24",

}

TY - JOUR

T1 - Alternate-day treatment with crizotinib for drug-induced esophagitis and liver damage in a patient with EML4-ALK fusion gene-positive lung adenocarcinoma

AU - Tsukita, Yoko

AU - Fukuhara, Tatsuro

AU - Kobayashi, Maki

AU - Morita, Mami

AU - Suzuki, Aya

AU - Watanabe, Kana

AU - Noguchi, Tetsuya

AU - Kurata, Yasuko

AU - Suno, Manabu

AU - Maemondo, Makoto

PY - 2015/12/15

Y1 - 2015/12/15

N2 - A 44-year-old woman who was diagnosed with anaplastic lymphoma kinase-positive lung adenocarcinoma developed brain metastases, multiple spinal metastases and meningeal dissemination. Crizotinib was administered after the failure of first-line chemotherapy. Esophagitis and liver damage were induced by the twicedaily administration of crizotinib at 250 mg and 200 mg, respectively. The alternate-day administration of crizotinib (250 mg, twice daily) was able to control disease progression without any adverse effects for several months. We evaluated the relationship between the serum concentration of crizotinib and the development of esophagitis and liver damage. The alternate-day administration of crizotinib is one of the strategies for managing the severe toxicity of crizotinib.

AB - A 44-year-old woman who was diagnosed with anaplastic lymphoma kinase-positive lung adenocarcinoma developed brain metastases, multiple spinal metastases and meningeal dissemination. Crizotinib was administered after the failure of first-line chemotherapy. Esophagitis and liver damage were induced by the twicedaily administration of crizotinib at 250 mg and 200 mg, respectively. The alternate-day administration of crizotinib (250 mg, twice daily) was able to control disease progression without any adverse effects for several months. We evaluated the relationship between the serum concentration of crizotinib and the development of esophagitis and liver damage. The alternate-day administration of crizotinib is one of the strategies for managing the severe toxicity of crizotinib.

KW - ALK rearrangement

KW - Alternate-day administration

KW - Crizotinib

KW - Drug-induced esophagitis

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84949817340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949817340&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.54.4996

DO - 10.2169/internalmedicine.54.4996

M3 - Article

C2 - 26666609

AN - SCOPUS:84949817340

SN - 0918-2918

VL - 54

SP - 3185

EP - 3188

JO - Internal Medicine

JF - Internal Medicine

IS - 24

ER -

Alternate-day treatment with crizotinib for drug-induced esophagitis and liver damage in a patient with EML4-ALK fusion gene-positive lung adenocarcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this